Aspire Life Sciences Search

We are seeking a Director of FEP Methods Development to join a leading biotechnology company that is transforming drug design for critical diseases through advanced technology. If you have a strong background in biotechnology, data analysis, and AI, and are passionate about shaping the future of medicine, we encourage you to apply today! #ApplyNow #AspireLifeScience #CareerOpportunity #Biotechnology #FreeEnergy #FEP https://lnkd.in/dBjvbzM9

Exciting Opportunity: Head of Global Market Expansion. Join a rapidly growing biopharmaceutical company to drive market growth in emerging regions, collaborating directly with the CEO and leading the charge in developing export strategies. If you're a strategic leader ready to make a global impact, we want to hear from you! #Applynow #AspireLifeScience #Dubai #UAE #CareerOpportunity #Internationalmarkets #Globalmarketexpansion https://lnkd.in/dDk6SX56

We are seeking a Director of FEP for Drug Discovery to join a leading biotechnology company that is transforming drug design for critical diseases through advanced technology. If you have a strong background in biotechnology, data analysis, and AI, and are passionate about shaping the future of medicine, we encourage you to apply today! #ApplyNow #AspireLifeScience #UnitedKingdom #CareerOpportunity #Biotechnology #FreeEnergy https://lnkd.in/dBjvbzM9

We are seeking a Free Energy Team Lead to join a leading biotechnology company that is transforming drug design for critical diseases through advanced technology. If you have a strong background in biotechnology, data analysis, and AI, and are passionate about shaping the future of medicine, we encourage you to apply today! #ApplyNow #AspireLifeScience #France #Paris #CareerOpportunity #Biotechnology #FreeEnergy #FreeEnergyTeamlead https://lnkd.in/dBjvbzM9

Join a leading global biotechnology company in Sweden as a Software Engineering Team Lead, where you'll manage a team, oversee software design and development for radio pharmacy cyclotrons, and drive innovative projects with a focus on integrating Artificial Intelligence. Apply now to be a part of this cutting edge team and make a significant impact in the field! https://lnkd.in/dGTtqqBG #AspireLifeSciences #ApplyNow #Sweden #SoftwareEngineeringTeamLead #CareerOpportunity #Software #Computescience

James Trott September Newsletter is now live, https://lnkd.in/ecKxc6ZJ

Exciting advancements in next-gen treatments, plus TechBio roles like Senior Computational Chemist and Data Analyst in France, Berlin, and London. Explore my "Lab to Leadership" blog for career insights, and check our team’s one-pager for specialised recruitment expertise.

Join a leading pharmaceutical company committed to global health innovations as a Senior Accountant. Bring your accounting expertise and pharmaceutical industry experience to oversee financial reporting and support our mission to transform lives. Apply now to be a part of something impactful! #AspireLifeSciences #SeniorAccountant #ApplyNow #Finance #CareerOpportunity https://lnkd.in/dCZ8Eike

Vitestro, a pioneer in medical robotics, has just achieved a major milestone with its automated blood drawing device receiving CE marking! This marks the first time ever that an autonomous blood drawing device has been approved for commercial use across the European Union, setting a new standard in healthcare automation. This cutting-edge technology, combining advanced imaging and robotics, is poised to transform blood sample collection by enabling accurate autonomous draws, reducing manual handling, and improving patient and clinician satisfaction. It's an incredible step forward, especially as clinical labs face staffing shortages. The team at Vitestro, led by CEO Toon Overbeeke, is paving the way for a future where European hospitals can independently perform invasive medical procedures using autonomous technology. With several leading hospitals already placing orders, the next 12 months will see these devices being implemented across Europe, starting in the Netherlands and Denmark. https://lnkd.in/esTti4FG #MedicalRobotics #HealthcareInnovation #Aspire #Vitestro

AstraZeneca has received marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) for its Imfinzi (durvalumab) regimen to treat adults with resectable non-small cell lung cancer (NSCLC). This approval allows the anti-PDL1 antibody to be used alongside platinum-based chemotherapy before surgery and as an adjuvant monotherapy post-surgery for patients without known epidermal growth factor receptor mutations or ALK rearrangements. Supported by positive results from the AEGEAN trial, Imfinzi demonstrated a 32% reduction in the risk of recurrence, progression, or death compared to neoadjuvant chemotherapy alone. The approval marks a significant advancement in NSCLC treatment, offering new hope for long-term survival. We at Aspire Life Sciences applaud this milestone and look forward to seeing its impact on patient outcomes. #AspireLifeSciences #CancerTreatment #LungCancer #MedicalInnovation #AstraZeneca https://lnkd.in/d_NdXihZ